Shares of Adverum Biotechnologies (ADVM) have gained 3.3% over the past four weeks to close the last trading session at $6.94, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $30 indicates a potential upside of 332.3%.The mean estimate comprises seven short-term price targets with a standard deviation of $11.02. While the lowest estimate of $12 indicates a 72.9% increase from th ...